| Today’s Big NewsAug 11, 2023 |
| By Max Bayer Bristol Myers Squibb has laid off more than 100 employees amid a reconfiguration of expenses that follows disappointing earnings results. |
|
|
|
By Conor Hale The Securities and Exchange Commission has begun its own investigation into Illumina’s ill-fated acquisition of Grail—a multibillion-dollar quest first launched nearly three years ago. |
By Nick Paul Taylor The dream of using anti-CD47 drugs to boost chemotherapy in blood cancer patients is unraveling fast. Weeks after Gilead Sciences stopped its phase 3 trial for futility, ALX Oncology has called a halt to a pair of studies for a rival therapy. |
By Nick Paul Taylor Atreca is taking drastic action to keep the show on the road into next year. With its cash running low and share price in the basement, the biotech has decided to stop work on its lead candidate, switch its focus to preclinical antibody-drug conjugates and lay off 40% of its staff. |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now.
|
|
By Kevin Dunleavy The Supreme Court has halted Purdue Pharma’s $6-billion bankruptcy settlement, which granted the company’s former owners—the Sackler family—immunity from civil suits related to the opioid crisis. |
By Andrea Park Fulfilling an imperative laid out years ago, Imperative Care has reorganized into a parent company overseeing four distinct businesses, each developing a different set of technologies to improve care for strokes and other vascular diseases. |
By Fraiser Kansteiner Less than a month after the family of Henrietta Lacks reached a settlement with Thermo Fisher over its use of Lacks’ cells, another drugmaker stands accused of profiting from a racist medical system. |
By Conor Hale Abiomed has identified 27 cases where the stentlike struts on the outer edge of the TAVR implant have connected with the Impella’s spinning blades. |
By Fraiser Kansteiner Frank Han, Pfizer's former director of global compliance analytics, has filed a civil complaint against the drugmaker. Han claims he was terminated for identifying potential issues relating to the Foreign Corrupt Practices Act. |
By Max Bayer,Gabrielle Masson A topsy turvy year for Mirati has taken its latest turn, with CEO David Meek stepping down this week effective immediately. |
By Angus Liu Amylyx’s amyotrophic lateral sclerosis drug Relyvrio continues to wow Wall Street. The drug brought in $98.2 million revenue in the second quarter, handily beating analysts’ consensus estimates of below $92 million. |
Fierce podcastsDon’t miss an episode |
| This week on "The Top Line," we discuss left-handedness and its significance in neurodevelopmental and psychiatric disorder research. |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now.
|
|
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Thermo Fisher Scientific Process Liquid Preparation Services |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperIn oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchLearn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
